Goldman Sachs
BRLI

Goldman Sachs’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Goldman Sachs’s Portfolio BRLI Stock Details BRLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-53,662
Closed -$2.21M – 7726
2015
Q2 		$2.21M Buy
53,662
+29,940
+126% +$1.07M ﹤0.01% 3736
2015
Q1 		$836K Buy
23,722
+2,438
+11% +$82.5K ﹤0.01% 4641
2014
Q4 		$684K Buy
21,284
+17,162
+416% +$496K ﹤0.01% 4970
2014
Q3 		$116K Buy
+4,122
New +$126K ﹤0.01% 6514
2014
Q2 		– Sell
-16,148
Closed -$447K – 7284
2014
Q1 		$447K Sell
16,148
-56,322
-78% -$1.47M ﹤0.01% 5388
2013
Q4 		$1.85M Buy
72,470
+35,038
+94% +$1.08M ﹤0.01% 4144
2013
Q3 		$1.12M Buy
37,432
+16,659
+80% +$463K ﹤0.01% 4503
2013
Q2 		$597K Buy
+20,773
New +$572K ﹤0.01% 4792

Other funds holding BRLI

SAM
Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return

Goldman Sachs's BRLI Position: Q3 2015 in Review

Goldman Sachs sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q3 2015, closing a stake of 53,662 shares — an estimated $2.21M sold.

Goldman Sachs first reported a position in BRLI in Q2 2013 and held it in 8 quarters. The position peaked at $2.21M in Q2 2015. 1 fund tracked by Wall St. Rank holds BRLI as of Q3 2015.

  • Goldman Sachs reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q3 2015 after selling out during the quarter.
  • Goldman Sachs sold 53,662 BIO-REFERENCE LABS INC-NEW- shares in Q3 2015, an estimated $2.21M.
  • Goldman Sachs first reported a position in BIO-REFERENCE LABS INC-NEW- in Q2 2013 and held it in 8 quarters.
  • Goldman Sachs's BIO-REFERENCE LABS INC-NEW- position peaked at $2.21M in Q2 2015.
  • 1 fund tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q3 2015.

Based on Goldman Sachs's 13F filing for Q3 2015, filed 13 Nov 2015.